Two Drug-Pricing Claims, Two Different Programs, and Savings That Don't Start Until 2027

Healthcare Source: Facebook Post MISLEADING

Original source →

Why This Matters for NY-23

NY-23 has one of the oldest populations in New York, with high Medicare enrollment in every county. Prescription drug prices — particularly for diabetes, cardiovascular, and cancer drugs — are a primary cost burden on rural seniors. When a member of Congress describes specific drug-savings figures as the results of his own “healthcare reform” without identifying the programs those figures actually come from, constituents lose the ability to know which policies are producing the results they see and which are being claimed without attribution.

Statement

Source: Facebook post, Rep. Langworthy’s official page Date: May 29, 2026 (approximately 22 hours before this fact-check)

“Reforming healthcare means putting patients first and the results are already underway: more than 600 generics added, direct discounts, and Medicare savings of 44%. That’s $12 billion in savings on 15 major drugs. That means lower costs and more money back for seniors and families.”

The post contains three numerical claims and a timing claim (“already underway”). The numbers are real, but they come from two separate programs with very different origins — and the largest portion does not take effect until January 1, 2027.

Claim 1: “More than 600 generics added” — Trump administration initiative, May 2026

The “more than 600 generics” figure refers to TrumpRx.gov, an executive-branch initiative announced by the Trump administration on May 18, 2026. The program partners with Amazon Pharmacy, Cost Plus Drugs, and GoodRx to list discounted prices on more than 600 generic medications.

TrumpRx.gov is not legislation. It does not involve a congressional vote. It is an HHS / White House program operating under existing executive authority.

Source: U.S. News, “Trump to Announce Discount Drug Pricing Expansion,” May 18, 2026.

In plain language: Langworthy did not pass a law to add 600 generics. The 600 generics come from a Trump administration website launched eleven days before his post.

Claim 2: “Medicare savings of 44% / $12 billion on 15 major drugs” — Inflation Reduction Act, effective January 1, 2027

These two figures describe Round 2 of the Medicare Drug Price Negotiation Program, created by §11001 of the Inflation Reduction Act (P.L. 117-169) and codified at Social Security Act §§ 1191–1198.

  • 15 drugs were selected for Round 2 negotiation in 2025.
  • CMS projects $12 billion in net savings relative to 2024 prices across those 15 drugs.
  • The average price reduction is 44% (“Maximum Fair Price” vs. 2024 list price); CMS estimates ~36% net of existing rebates.
  • The negotiated prices take effect January 1, 2027 — not “already.”
  • Approximately 1.8 million Medicare beneficiaries are projected to be affected, with an estimated $685 million in Part D out-of-pocket savings in 2027 alone.

The 15 drugs (Maximum Fair Price effective January 1, 2027)

#BrandManufacturerTreatsList → MFP / 30-dayDiscount
1Ozempic / Rybelsus / WegovyNovo NordiskType 2 diabetes / weight loss$959 → $27471%
2Trelegy ElliptaGSKAsthma / COPD$654 → $17573%
3Breo ElliptaGSKAsthma / COPD$397 → $6783%
4XtandiAstellas / PfizerProstate cancer$13,480 → $7,00448%
5PomalystBristol Myers SquibbMultiple myeloma$21,744 → $8,65060%
6IbrancePfizerBreast cancer$15,741 → $7,87150%
7CalquenceAstraZenecaMantle-cell lymphoma / CLL$14,228 → $8,60040%
8OfevBoehringer IngelheimIdiopathic pulmonary fibrosis$12,622 → $6,35050%
9LinzessAbbVie / IronwoodIBS-C$539 → $13675%
10XifaxanSalix (Bausch Health)IBS-D / hepatic encephalopathy$2,696 → $1,00063%
11Austedo / Austedo XRTevaHuntington’s chorea / tardive dyskinesia$6,623 → $4,09338%
12VraylarAbbVieSchizophrenia / bipolar / depression$1,376 → $77044%
13OtezlaAmgenPsoriasis / psoriatic arthritis$4,722 → $1,65065%
14TradjentaBoehringer Ingelheim / LillyType 2 diabetes$488 → $7884%
15Janumet / Janumet XRMerckType 2 diabetes$526 → $8085%

For comparison, Round 1 covered 10 drugs and took effect January 1, 2026, producing approximately $6 billion in savings (~22% net).

Sources: CMS press release, “CMS Delivers Savings for Seniors on 15 Major Drugs for Cancer and Chronic Disease” (Nov. 25, 2025); CMS, “Selected Drugs and Negotiated Prices”; CMS Infographic, “Negotiated Prices IPAY 2027” (PDF); KFF, “Key Facts About Medicare Drug Price Negotiation”; Federal Register, “IRA Medicare Drug Price Negotiation Program Final Guidance” (Nov. 28, 2025).

In plain language: The $12 billion and 44% are real — and they come from the Inflation Reduction Act, a 2022 law every House Republican voted against. The savings on those 15 drugs do not begin until January 1, 2027 — about seven months from this post. Of particular note for an aging rural district like NY-23: three of the 15 drugs treat Type 2 diabetes (Ozempic/Wegovy, Tradjenta, Janumet), two are COPD/asthma inhalers (Trelegy, Breo), and three are major cancer treatments (Xtandi for prostate, Pomalyst for myeloma, Ibrance for breast).

Claim 3: “The results are already underway”

For the TrumpRx.gov generic prices (Claim 1), this is accurate.

For the 44% / $12 billion / 15 drugs (Claim 2), this is not accurate. Those negotiated prices take effect January 1, 2027. The savings have not begun for the 15 drugs at issue. Round 1 (10 drugs) prices did take effect January 1, 2026 — but those produced ~$6 billion in projected savings, not the $12 billion the post cites.

Langworthy’s Record on the Underlying Law

Langworthy was not yet a Member of Congress when the Inflation Reduction Act passed on August 12, 2022 (House Roll Call 420, 220–207). He won his Republican primary 11 days later, on August 23, 2022, and was sworn in to the 118th Congress on January 3, 2023.

He did not personally cast a vote against the IRA. Every House Republican who was in Congress at the time voted no (207 Nay, 0 Republican Yea). The Medicare Drug Price Negotiation Program — the source of the 44% and $12 billion figures the post cites — was created by §11001 of that law, which passed without a single Republican vote.

How OBBBA affected the negotiation program — and how Langworthy voted

Langworthy voted YES on the One Big Beautiful Bill Act (P.L. 119-21, Roll Call 190, July 3, 2025). OBBBA did not repeal the negotiation program. The Round 1 and Round 2 prices (the figures the post cites) were unaffected.

OBBBA did, however, include Section 71203 — the so-called “ORPHAN Cures Act” provision — which expanded the orphan-drug carve-out from the Medicare Drug Price Negotiation Program. Section 71203 broadens which drugs are exempt from negotiation by allowing exemption when a drug has multiple orphan-disease indications (the IRA had limited the exemption to single-indication orphan drugs) and shifts the negotiation-eligibility clock so the 7/11-year countdown only starts when a drug receives a non-orphan approval.

The Congressional Budget Office initially scored §71203 at approximately $4.9 billion in reduced Medicare savings over ten years; CBO revised the estimate upward to $8.8 billion in October 2025.

Section 71203 affects future negotiation rounds, not Round 1 (effective Jan. 1, 2026) or Round 2 (effective Jan. 1, 2027). But it directly reduces the size of future Medicare drug-price savings of the same type the post is celebrating.

Sources: clerk.house.gov Roll Call 420 (Aug. 12, 2022); clerk.house.gov Roll Call 190 (Jul. 3, 2025); P.L. 117-169 § 11001; P.L. 119-21 § 71203; CBO score updates (Oct. 2025); Morgan Lewis, Jones Day, Sidley Austin analyses (July 2025); Health Affairs Forefront, “Blockbusters and Loopholes” (2025).

What the Post Does and Doesn’t Say

What is documented:

  • The “600 generics” comes from TrumpRx.gov, a Trump-administration initiative announced May 18, 2026.
  • The “Medicare savings of 44% / $12 billion on 15 major drugs” comes from Round 2 of the IRA’s Medicare Drug Price Negotiation Program, effective January 1, 2027.
  • Langworthy was not in Congress for the IRA vote; the IRA passed with zero Republican votes.
  • The post identifies neither program by name, and presents future savings (“already underway”) as current.
  • Langworthy voted YES on OBBBA, which contained Section 71203 expanding the orphan-drug carve-out and reducing future Medicare drug-negotiation savings by an estimated $8.8 billion over ten years (CBO).

What is not documented:

  • Any legislation Langworthy authored, co-sponsored, or voted for that produced any of the three figures cited.

Verdict: MISLEADING

The figures cited are real, but the post:

  1. Conflates two separate programs (a Trump executive initiative and a 2022 Democratic-passed law) into one “healthcare reform” agenda without naming either.
  2. Describes savings that take effect January 2027 as “already underway.”
  3. Omits that the largest savings figure ($12 billion / 44% / 15 drugs) is produced by legislation Republicans unanimously opposed and which remained intact despite OBBBA.

A reader could reasonably conclude from the post that Langworthy or House Republicans authored the savings. The record shows otherwise.

Sources

All data from public primary sources. Methodology available on request.